SGI
LXRX icon

Summit Global Investments’s Lexicon Pharmaceuticals LXRX Stock Holding History

Summit Global Investments’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,700
Closed -$95K – 526
2021
Q2 		$95K Buy
+20,700
New +$99.7K 0.01% 553

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Summit Global Investments's LXRX Position: Q3 2021 in Review

Summit Global Investments sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2021, closing a stake of 20,700 shares — an estimated $95K sold.

Summit Global Investments first reported a position in LXRX in Q2 2021 and held it in 1 quarter. The position peaked at $95K in Q2 2021. 96 funds tracked by Wall St. Rank hold LXRX as of Q3 2021.

  • Summit Global Investments reported no remaining Lexicon Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Summit Global Investments sold 20,700 Lexicon Pharmaceuticals shares in Q3 2021, an estimated $95K.
  • Summit Global Investments first reported a position in Lexicon Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Summit Global Investments's Lexicon Pharmaceuticals position peaked at $95K in Q2 2021.
  • 96 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2021.

Based on Summit Global Investments's 13F filing for Q3 2021, filed 8 Nov 2021.